Navigation Links
USCCB Submits Comments to NIH on Proposed Guidelines for Stem Cell Research
Date:5/22/2009

USCCB General Secretary urges respect for human life at all stages

Says science and ethics have been ignored in proposed policy

Cites advances in stem cell research that do not destroy human embryos

WASHINGTON, May 22 /PRNewswire-USNewswire/ -- The National Institutes of Health (NIH) missed "an enormous opportunity to show how sound science and responsible ethics can not only co-exist but support and enrich each other," said Msgr. David Malloy, General Secretary of the U.S. Conference of Catholic Bishops (USCCB), in comments on draft guidelines to authorize federally funded human embryonic stem cell research. The comments were submitted during the official public comment period on the proposed guidelines, which ends May 26. The Conference has also provided a convenient way for other concerned citizens to submit comments to the NIH on this issue, by visiting the Web site www.usccb.org/stemcellcampaign.

Msgr. Malloy cited the dignity of human life at every stage and the innate human right not to be subjected to harmful experimentation without one's express and informed consent. He said laws that fail to recognize this right "do not succeed in nullifying the right in question, but only call into question their own moral legitimacy."

Msgr. Malloy highlighted the "central fact of science" relevant to the issue of embryonic stem cell research, that the embryo that will be destroyed to obtain embryonic stem cells "is a human being at a very early stage of his or her development."

This is not a matter of religious belief, he said, but a fact acknowledged by federal advisory groups on this issue, including the National Bioethics Advisory Commission appointed by President Clinton. This group concluded that because human embryos deserve "respect" as a form of human life, destroying them for stem cells is "justifiable only if no less morally problematic alternatives are available for advancing the research."

Msgr. Malloy added that alternative methods of stem cell research, such as reprogramming ordinary adult cells into "induced pluripotent stem cells" (iPS cells) without harming human life, have made great advances under a federal policy preventing researchers from destroying live human embryos for federally funded research.

"Yet President Obama's executive order of March 9 not only rescinded that policy, but also rescinded the executive order of 2007 instructing the NIH to thoroughly explore new avenues for obtaining pluripotent stem cells without destroying human embryos," Msgr. Malloy said. "Both science and ethics have been ignored in this decision."

Msgr. Malloy said the President's executive order and the draft guidelines fail the Bioethics Commission's test, "by failing to require that morally unproblematic avenues for exploring important medical research goals be thoroughly investigated before the NIH considers any avenues that require destroying embryonic human life."

"Avenues of stem cell research which pose no moral problem are now showing great promise. In fact, human patients suffering from all the conditions cited by President Obama when he signed his executive order -- cancer, juvenile diabetes, Parkinson's disease, spinal cord injury, heart disease -- have been shown in peer-reviewed studies to benefit from clinical trials using human stem cells," he said. "And in every case, the benefit has come not from embryonic stem cells, but from the adult and cord blood stem cells that this organization and others have said should receive priority attention."

Msgr. Malloy expressed relief the proposed guidelines do not seek to fund research in which embryos are created for the purpose of research, but explained how "in key respects the guidelines are nonetheless broader or more permissive than any policy approved in the past by any branch of the federal government.." He also asked the Obama Administration to "make a clear and authoritative statement, as the Clinton Administration did, that it will never fund research that relies on the creation of human embryos for research purposes."

"As the President noted," Msgr. Malloy said, "we must not make 'a false choice between sound science and moral values.' In fact, these sources of guidance both point in the same direction, away from destructive embryonic stem cell research. His executive order and these guidelines nonetheless insist on a course of action that is both morally objectionable and, increasingly, scientifically obsolete."

Noting that prominent stem cell researchers have recently expressed their own moral misgivings about destroying human embryos for research, Msgr. Malloy concluded, "This is not merely a political or ideological problem, or a problem of religious dogma, but a deeply human problem: We are testing the limits of our obligation to treat all fellow human beings, of every age and condition, with basic respect."

The full text of the comments to NIH regarding the draft guidelines can be found online at www.usccb.org/prolife/NIHcomments.pdf.


'/>"/>
SOURCE U.S. Conference of Catholic Bishops Secretariat for Pro-Life Activities
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. USCCB Official Praises Senate Passage of Genetic Information Nondiscrimination Act
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
4. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
7. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
10. Takeda submits new drug application for alogliptin (syr-322) in the US
11. Phyhealth Submits HMO Applications with Required Federal and State Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: